UNSPSC 51283955: Sulfathiazole sodium

This classification denotes a sulfonamide anti-infective agent with the molecular formula C9H8N3O2S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PV16N742VM, chemically known as sulfanilamide, n(sup 1)-2-thiazolyl-, n(sup 1)-sodium deriv. but more generally known as sulfathiazole sodium, which bears US NIH Compound Identifier 67415. Most nations, for tariff and trade purposes, schedule sulfathiazole sodium under HS 29350090 and SITC 51580. As of Q4 2014, SULFATHIAZOLE SODIUM remains US FDA's Preferred Term for this commodity.

SMILES: C1CC(CCC1N)S(=O)(=O)[N-]C2NCCS2.[NA+].

UNSPSC 51283955 Sulfathiazole sodium is a Commodity code that nominally names a single pharmaceutical chemical compound, but recent state and local solicitations tagged with this code show little activity actually purchasing sulfathiazole sodium itself. Instead, the code appears in procurement records for broader pharmaceutical and medical supply categories—naloxone systems, direct-to-manufacturer pharmacy programs, medical and first aid supplies for emergency responders, and generic multi-source pharmaceuticals and OTC products. The actual buying under this code span emergency medical supplies, pharmacy benefit management initiatives, and bulk pharmaceutical distribution, suggesting the code may be mislabeled in source databases or used as a catch-all tag for pharmaceutical-related procurements. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance). The scope reflects what state and local governments actually need in practice: emergency medical consumables with tight delivery windows, pharmacy benefit restructuring to improve cost control, and standardized medical supplies for first responders.

Recent activity appears concentrated in Florida and the Upper Midwest, with secondary activity from Texas. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, closing July 26, 2023. The City of Tampa issued an ITB (26P00145) on March 25, 2026, for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000, designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline, requiring manufacturers to supply through three authorized wholesalers and award effective July 1, 2026. Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling preliminary market research before a formal RFP. Set-asides vary by issuing body; Tampa's procurement carries explicit SLBE preference, while MMCAP does not identify specific disadvantaged-enterprise restrictions in available materials.